Hospitals enrolled in the 340B program will have to recertify their eligibility for reduced 340B drug pricing this year between Aug. 24 and Sept. 19, the U.S. Health Resources and Services Administration says.
340B covered entities must annually recertify their
…
If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary
…
Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use
…
Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.
…
For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website
…
Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Meanwhile, the federal government
…
Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Total sales would have been $93.6 billion if
…
A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for
…
Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.
According to Bausch’s announcement, effective Aug.
…
The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any
…*Sign up for news summaries and alerts from 340B Report